Table 1 Baseline clinical characteristics of the patients.
Pericardial effusion type | ||
|---|---|---|
Inflammatory (n = 55) | Non-inflammatory (n = 61) | |
Male sex, no. (%) | 28 (50.9) | 29 (49.2) |
Age years, median (IQR) | 55 (40–69) | 61 (49–71) |
Weight kg, median (IQR) | 65 (56.8–73.4) | 63.7 (56–73) |
Height m, (IQR) | 1.64 (1.55–1.70) | 1.60 (1.53–1.70) |
Signs and symptoms, n (%) | ||
Asymptomatic (%) | 3 (5.5) | 3 (4.9) |
Dyspnea | 23 (41.8) | 27 (44.3) |
Hypotension | 12 (21.8) | 20 (32.8) |
Tachycardia | 2 (3.6) | 4 (6.6) |
Pericardial chest pain | 21 (38.2) | 10 (16.4) |
Cardiac arrest, shock, syncope | 2 (3.6) | 3 (4.9) |
NYHA functional class, n (%) | ||
I | 16 (29.1) | 14 (23.0) |
II | 26 (47.3) | 23 (37.7) |
III | 12 (21.8) | 18 (29.5) |
IV | 1 (1.8) | 6 (9.8) |
Pericardial effusion presentation, n (%) | ||
Large pericardial effusion without hemodynamic effect* | 15 (27.3) | 7 (11.5) |
Clinical manifestations cardiac tamponade with or without aborted cardiac arrest | 13 (23.6) | 22 (36.1) |
Echocardiographic signs of cardiac tamponade without clinical manifestations | 27 (49.1) | 32 (52.5) |
Other clinical characteristics, n (%) | ||
Anemia | 37 (67.3) | 38 (62.3) |
Renal replacement therapy | 1 (1.8) | 4 (6.6) |
Previous cardiac procedures | 36 (65.5) | 29 (47.5) |
Use of anticoagulants | 20 (36.4) | 22 (36.1) |
Anticoagulation therapy, n (%) | ||
Unfractionated heparin | 1 (1.8) | 9 (14.8) |
Low-molecular-weight heparin | 2 (3.6) | 6 (9.8) |
Warfarine | 15 (27.3) | 6 (9.8) |
Rivaroxaban | 2 (3.6) | 1 (1.6) |
